What it is
SLU-PP-332 is an experimental small-molecule oestrogen-related-receptor agonist described in academic publications. It is a laboratory research compound with no clinical development programme completed.
The Range
SLU5 · Pen · Metabolic research
SLU-PP-332 5 mg pen
Research-onlyEvidence: Preclinical
An early-stage experimental ERR agonist compound studied in animal models of exercise-related metabolism. Preclinical only.
Evidence highlights
Mechanism being studied
Reported to activate ERR isoforms associated with mitochondrial and oxidative metabolism pathways in rodent studies.
Human evidence
There is no human clinical evidence. It has not been evaluated for safety or efficacy in people.
Information only — availability subject to applicable law, prescription/authorisation, and licensed healthcare/pharmacy channels. Nothing on this page is an offer to sell, and no dosing or self-administration guidance is provided.
South Africa — compliance notice
SAHPRA has publicly warned about unregistered peptide products being marketed to the South African public. In general, products intended to diagnose, treat, or otherwise alter bodily functions require registration or authorisation before they may lawfully be sold. ELLIVON BIOSCIENCES publishes reference information only and directs all clinical questions to registered healthcare professionals and licensed pharmacy channels.